Mutated KRAS and RNF43 detected from tumors, cyst fluid, pancreatic juice, and blood cell‐free DNA may serve as novel biomarkers of advanced neoplasia in the molecular surveillance and stratification for IPMN patients. This evidence concerns the gene RNF43 and pancreatic intraductal papillary-mucinous neoplasm.